TABLE 3.

Uni‐ and multivariate Cox regression regarding PFS at baseline and after 8–12 weeks of therapy. Multivariable analysis was adjusted for tumor type. HR – hazard ratio

Variable	Univariable analysis		Multivariable analysis
	HR (95% CI)	p‐value	HR (95% CI)	p‐value
1st blood draw (baseline)
Any autoantibody
Negative	1 (reference)		1 (reference)
Positive	1.131 (0.584–2.189)	0.715	0.944 (0.457–1.950)	0.876
ANA
<1:80 (negative)	1 (reference)		1 (reference)
≥1:80 (positive)	0.971 (0.492–1.917)	0.933	0.801 (0.377–1.703)	0.565
2nd blood draw
Any autoantibody
Negative	1 (reference)		1 (reference)
Positive	1.317 (0.567–3.061)	0.522	0.923 (0.343–2.482)	0.874
ANA
<1:80 (negative)	1 (reference)		1 (reference)
≥1:80 (positive)	0.834 (0.362–1.922)	0.670	0.405 (0.145–1.138)	0.086
ANA level change
No increase	1 (reference)		1 (reference)
Increase	0.825 (0.338–2.011)	0.672	0.614 (0.245–1.540)	0.298

Abbreviations: ANA, antinuclear antibody; CI, confidence interval; DCR, disease control rate; ORR, objective response rate.